Personal information

Chronic myeloid leukemia, myeloproliferative neoplasms

Biography

Ahmet Emre Eşkazan, MD, is a Professor of Internal Medicine and Hematology currently working in the Division of Hematology, Department of Internal Medicine at the Cerrahpaşa Faculty of Medicine of the Istanbul University-Cerrahpaşa, Istanbul. He was graduated from Cerrahpaşa Faculty of Medicine in 1999 and completed his internal medicine residency and hematology fellowship at the same institute in 2005 and 2010, respectively. He is an active member of Turkish Society of Hematology (TSH), European Hematology Association (EHA), American Society of Hematology, and American Society of Clinical Oncology. He is also the Society of Hematologic Oncology (SOHO) Ambassador to Turkey. He is currently the head of chronic myeloid leukemia (CML) and myeloproliferative neoplasm (MPN) Scientific Subcommittee of TSH and he is a member of the EHA Scientific Working Group on CML. He is also a member for the European Board for Accreditation in Hematology (EBAH). Dr Eşkazan has authored more than 170 peer-reviewed publications. His main research topics are myeloid malignancies including, CML, MPNs, and acute myeloid leukemia.

Activities

Employment (1)

Istanbul University-Cerrahpaşa: Istanbul, TR

Professor (Department of Internal Medicine, Division of Hematology)
Employment
Source: Self-asserted source
Ahmet Emre Eşkazan

Education and qualifications (3)

Istanbul University Cerrahpasa Faculty of Medicine: Istanbul, TR

2007 to 2010 | Hematologist (Department of Internal Medicine, Division of Hematology)
Education
Source: Self-asserted source
Ahmet Emre Eşkazan

Istanbul University Cerrahpasa Faculty of Medicine: Istanbul, TR

2000 to 2005 | Internist (Department of Internal Medicine)
Education
Source: Self-asserted source
Ahmet Emre Eşkazan

Istanbul University Cerrahpasa Faculty of Medicine: Istanbul, TR

1993 to 1999 | Medical Doctor
Education
Source: Self-asserted source
Ahmet Emre Eşkazan

Works (50 of 158)

Items per page:
Page 1 of 4

Complications of therapeutic plasma exchange: A retrospective, single‐center study of 2505 procedures performed in 338 patients over 15 years

Therapeutic Apheresis and Dialysis
2024-12 | Journal article
Contributors: Ece Vural; Tuğrul Elverdi; Ayşe Salihoğlu; Muhlis Cem Ar; Şeniz Öngören; Zafer Başlar; Teoman Soysal; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Unusual synchronous and metachronous association of hematologic neoplasms with gynecologic neoplasms: A case series and literature review

International Journal of Gynecology & Obstetrics
2024-12-06 | Journal article
Contributors: Ipek Betul Ozcivit Erkan; Oguzhan Kuru; Cansu Turker Saricoban; Marwa Wardak; Kubra Hamzaoglu Canbolat; Ahmet Emre Eskazan
Source: check_circle
Crossref

Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma

Journal of Chemotherapy
2024-07-03 | Journal article
Contributors: Umut Yılmaz; Güldane Zulfaliyeva; Adnan Nuri Güzelli; Deniz Özmen; Tuğrul Elverdi; Ayşe Salihoğlu; Ahmet Emre Eskazan; Şeniz Öngören; Zafer Başlar; Muhlis Cem Ar
Source: check_circle
Crossref

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

Expert Review of Hematology
2024-07-02 | Journal article
Contributors: Betül Saydan; Deniz Özmen; Ahmet Emre Eşkazan
Source: check_circle
Crossref

A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

Expert Opinion on Drug Safety
2024-04 | Journal article
Contributors: Deniz Özmen; Duygu Demet Alpaydın; Muhammed Ali Saldoğan; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?

Oncology and Therapy
2024-03 | Journal article
Contributors: Umut Yılmaz; Selin Küçükyurt; Muhlis Cem Ar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

Pleura and Peritoneum
2024-03-30 | Journal article
Contributors: Selin Küçükyurt; Tuğçe Eşkazan; Mesut Ayer; Burçak Kılıçkıran Avcı; İbrahim Hatemi; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Treatment of anemia in myelofibrosis: focusing on novel therapeutic options

Expert Opinion on Investigational Drugs
2024-01-02 | Journal article
Contributors: Eren Arslan Davulcu; Merve Beyza Oğuz; Emre Kılıç; Ahmet Emre Eşkazan
Source: check_circle
Crossref

A cross-sectional study on restless legs syndrome (RLS) in polycythemia vera (PV): is iron deficiency the only culprit?

Neurological Research
2023-12-02 | Journal article
Contributors: Duygu Seyhan Erdoğan; Gülçin Benbir Şenel; Ayşegül Gündüz; Beria Peren Uçar; Tuğrul Elverdi; Ayşe Salihoğlu; Muhlis Cem Ar; Şeniz Öngören; Zafer Başlar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults

Expert Opinion on Pharmacotherapy
2023-10-13 | Journal article
Contributors: Sinan Mersin; Fatih Gülük; Emirhan Gülcan; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Cancer
2023-09 | Journal article
Contributors: Eda Nuhoğlu Kantarcı; Ece Tolgay; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Flow Cytometric Analysis of Lymphocyte Subsets of Covid-19 Patients from A Single Centre in Turkey

Acibadem Universitesi Saglik Bilimleri Dergisi
2023-09-20 | Journal article
Contributors: Tuğrul ELVERDİ; Abdülkadir ERÇALIŞKAN; Rıdvan KARAALİ; İlker İnanç BALKAN; Deniz ÖZMEN; Ayşe SALİHOĞLU; Birgül METE; Ahmet Emre EŞKAZAN; Zafer BAŞLAR; Fehmi TABAK et al.
Source: check_circle
Crossref

Plasma exchange therapy in systemic lupus erythematosus: A single-center retrospective cohort study

Ulusal Romatoloji Dergisi
2023-07-28 | Journal article
Contributors: Yeşim Özgüler; Tümay Ak; Sinem Nihal Esatoğlu; Tuğrul Elverdi; Ahmet Emre Eşkazan; Serdal Uğurlu; Gülen Hatemi; Emire Seyahi; Melike Melikoğlu; İzzet Fresko et al.
Source: check_circle
Crossref

Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!

Cancer
2023-07-15 | Journal article
Contributors: Ahmet Emre Eşkazan
Source: check_circle
Crossref

Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial

Oncology and Therapy
2023-06 | Journal article
Contributors: Emine Eylem Genç; İrem Sena Saraç; Hayrunnisa Arslan; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

Hematology, Transfusion and Cell Therapy
2023-04 | Journal article
Contributors: Selin Küçükyurt; Alihan Kelezoğlu; Tuğrul Elverdi; Deniz Özmen; Muhlis Cem Ar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Elevación de SPINK2 en leucemia mieloide aguda

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
2023-04-11 | Journal article
Contributors: Sümbül Gezer; Zeliha Emrence; Tuğrul Elverdi; Muhlis Cem Ar; Burcu Salman Yaylaz; Ferda Paçal; Ayşegül Ünüvar; Melda Sarıman; Ahmet Emre Eşkazan; Serap Karaman et al.
Source: check_circle
Crossref

Upregulation of SPINK2 in acute myeloid leukemia

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
2023-04-11 | Journal article
Contributors: Sümbül Gezer; Zeliha Emrence; Tuğrul Elverdi; Muhlis Cem Ar; Burcu Salman Yaylaz; Ferda Paçal; Ayşegül Ünüvar; Melda Sarıman; Ahmet Emre Eşkazan; Serap Karaman et al.
Source: check_circle
Crossref

ATRA+ATO combination in APL – A commentary on “evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades” by Teng-Fei et al.

Translational Oncology
2023-03 | Journal article
Contributors: Damla Ortaboz; Mehmed Semih Çetin; Burak Cömert; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting

Future Oncology
2023-03 | Journal article
Contributors: Reyhan Yılmaz; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!

Cancer
2023-02-15 | Journal article
Contributors: Ahmet Emre Eşkazan
Source: check_circle
Crossref

Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review

Expert Review of Hematology
2023-02-01 | Journal article
Contributors: Mehmet Baysal; Meltem Bayrak; Ahmet Emre Eşkazan
Source: check_circle
Crossref

A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?

Clinical Lymphoma Myeloma and Leukemia
2023-01 | Journal article
Contributors: Rafiye Çiftçiler; Mehmet G. Akın; Zeynep Erat; A. Emre Eşkazan
Source: check_circle
Crossref

Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

International Journal of Hematology
2023-01 | Journal article
Contributors: Zehra Narlı Özdemir; Necati Alp Kılıçaslan; Musa Yılmaz; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Plasma exchange therapy in ANCA-associated vasculitis: A single-center retrospective cohort study

Ulusal Romatoloji Dergisi
2022-12-01 | Journal article
Contributors: Yeşim Özgüler; Tümay Ak; Sinem Nihal Esatoğlu; Tuğrul Elverdi; Ahmet Emre Eşkazan; Serdal Uğurlu; Gülen Hatemi; Emire Seyahi; Melike Melikoğlu; İzzet Fresko et al.
Source: check_circle
Crossref

A new dawn for upfront autologous SCT in NK/T‐cell lymphomas: One more step forward in reasoning

International Journal of Cancer
2022-09 | Journal article
Contributors: Tuğrul Elverdi; Mustafa Furkan Hıyamlı; Betül Şahin; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Recent Advances in the Therapeutic Armamentarium of Acute Myeloid Leukemia: A Focus on the 63rd American Society of Hematology Annual Meeting Abstracts

Current Pharmaceutical Design
2022-09 | Journal article
Contributors: Eşref Alperen Bayraktar; Selin Küçükyurt; Ahmet Emre Eşkazan
Source: check_circle
Crossref

A Rare and Aggressive Disease: Answer

The American Journal of Dermatopathology
2022-08 | Journal article
Contributors: Özge Sönmez; Selin Küçükyurt; Ayşe Mine Önenerk Men; Ahu Senem Demiröz; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?

Expert Review of Respiratory Medicine
2022-08-03 | Journal article
Contributors: Necati Alp Kılıçaslan; Şermin Börekçi; Gül Nihal Özdemir; Müge Sayitoğlu; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Is it possible to predict the pCR with CBC? A commentary on “correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer” by Meng et al.

Translational Oncology
2022-06 | Journal article
Contributors: Eda Tanrıkulu Şimşek; Batuhan Bayram; Alev Yıldırım; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Spotlight Commentary – Voxelotor: A new kid on the block in the treatment of sickle cell disease

British Journal of Clinical Pharmacology
2022-06 | Journal article
Contributors: Betül Çanak; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades

Cancer Management and Research
2022-06 | Journal article
Contributors: Simay Çokgezer; Tuğrul Elverdi; Ayşe Salihoğlu; Muhlis Cem Ar; Şeniz Öngören; Zafer Başlar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.

Translational Oncology
2022-05 | Journal article
Contributors: Özden Hatırnaz Ng; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review

Expert Review of Hematology
2022-05-04 | Journal article
Contributors: Umut Yılmaz; Batuhan Bulan; Çağrı Belli; Ahmet Emre Eşkazan
Source: check_circle
Crossref

The Effect of Comorbidities on the Choice of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

International Journal of Hematologic Oncology
2022-03 | Journal article
Contributors: Guray Saydam; Ridvan Ali; Ahmet Muzaffer Demir; Ahmet Emre Eskazan; Birol Guvenc; Ibrahim Celalettin Haznedaroglu; Mehmet Ali Ozcan; Ozan Salim; Mehmet Sonmez; Ayse Tulin Tuglular et al.
Source: check_circle
Crossref

<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet’s Disease

Molecular Imaging and Radionuclide Therapy
2022-02-02 | Journal article
Contributors: Burak İnce; Ali Kibar; Sertaç Asa; Rabia Lebriz Uslu Beşli; Muhammet Sait Sağer; Ahmet Emre Eşkazan; Ali İbrahim Hatemi; Gülen Hatemi; Kerim Sönmezoğlu
Source: check_circle
Crossref

Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

Expert Review of Hematology
2022-02-01 | Journal article
Contributors: Ahmet Emre Eşkazan; Rıdvan Ali; Ebru Alnıgeniş; Orhan Ayyıldız; İbrahim Haznedaroğlu; Onur Kırkızlar; Erdal Kurtoğlu; Simten Malhan; Ergün Öksüz; Özlem Polat et al.
Source: check_circle
Crossref

Asciminib as a new option in the treatment of chronic myeloid leukemia

Future Oncology
2021-12 | Journal article
Contributors: Betül İbiş; Mario Tiribelli; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

Expert Review of Hematology
2021-11-02 | Journal article
Contributors: Sara Malik; Shahzeb Hassan; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al

Journal of Thrombosis and Haemostasis
2021-10 | Journal article
Contributors: Tahacan Aydın; Tuğrul Elverdi; Melis Dila Özer Çerme; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

Expert Review of Clinical Pharmacology
2021-10-03 | Journal article
Contributors: Tuğrul Elverdi; Melis Dila Özer Çerme; Tahacan Aydın; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs

Blood Advances
2021-09-14 | Journal article
Contributors: Abdülkadir Erçalışkan; Duygu Seyhan Erdoğan; Ahmet Emre Eşkazan
Source: check_circle
Crossref

New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on “C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases”

Translational Oncology
2021-08 | Journal article
Contributors: Selin Küçükyurt; Furkan Bahar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

A clinical appraisal of chronic myeloid leukaemia (CML)‐related death and CML‐specific death—Are they synonymous?

International Journal of Clinical Practice
2021-06 | Journal article
Contributors: Ahmet Emre Eşkazan
Source: check_circle
Crossref

What is the best treatment approach for sporadic late‐onset nemaline myopathy associated with “monoclonal gammopathy of neurological significance”?

International Journal of Cancer
2021-06 | Journal article
Contributors: Ahmet Emre Eşkazan; Ayşegül Gündüz
Source: check_circle
Crossref

Candida esophagitis incidentally detected by 18F‐FDG PET/CT in a patient with CNS lymphoma

Clinical Case Reports
2021-05 | Journal article
Contributors: Melikşah Bayar; Nurgül Özgür Yurttaş; Seçkin Bilgiç; Kebire Karakuş; Uğur Önal; Kerim Sönmezoğlu; Zafer Başlar; Ahmet Emre Eşkazan
Source: check_circle
Crossref

Asciminib in chronic myeloid leukemia: many questions still remain to be answered

Blood Cancer Journal
2021-04-29 | Journal article
Contributors: Ahmet Emre Eşkazan
Source: check_circle
Crossref

Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

Expert Opinion on Drug Safety
2021-04-03 | Journal article
Contributors: Mebrure Burçak Yüzbaşıoğlu; Ahmet Emre Eşkazan
Source: check_circle
Crossref

The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia

TURKISH JOURNAL OF MEDICAL SCIENCES
2021-02-26 | Journal article
Contributors: Sinem Nihal ESATOĞLU; Dilek KESKİN; Ahmet Emre EŞKAZAN; Tuğrul ELVERDİ; Ayşe SALİHOĞLU; Muhlis Cem AR; Şeniz ÖNGÖREN; Zafer BAŞLAR; Yıldız AYDIN; Hafize UZUN et al.
Source: check_circle
Crossref

COVID‐19 presenting with immune thrombocytopenia: A case report and review of the literature

Journal of Medical Virology
2021-01 | Journal article
Contributors: Ahmet Murt; Ahmet Emre Eskazan; Umut Yılmaz; Tuba Ozkan; Muhlis Cem Ar
Source: check_circle
Crossref
Items per page:
Page 1 of 4

Peer review (7 reviews for 6 publications/grants)

Review activity for Advances in therapy. (1)
Review activity for Blood reviews. (2)
Review activity for F1000Research. (1)
Review activity for Heliyon. (1)
Review activity for Nature communications (1)
Review activity for Pathology, research and practice. (1)